We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
-8.81%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$4.32B
AUM Growth
+$1.17B
(+37%)
Cap. Flow
+$268M
Cap. Flow
% of AUM
6.2%
Top 10 Holdings %
Top 10 Hldgs %
67.79%
Holding
43
New
10
Increased
9
Reduced
6
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$136M |
| 2 |
Humana
HUM
|
+$121M |
| 3 |
CVS Health
CVS
|
+$84.2M |
| 4 |
Cigna
CI
|
+$47.8M |
| 5 |
Evolent Health
EVH
|
+$45.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$96M |
| 2 |
SEM
Select Medical
SEM
|
+$74.1M |
| 3 |
Globus Medical
GMED
|
+$73M |
| 4 |
Baxter International
BAX
|
+$63.1M |
| 5 |
Universal Health Services
UHS
|
+$28.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.27% |
| 2 | Miscellaneous | 41.27% |
| 3 | Consumer Staples | 0.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ZIMV
26
DELISTED
ZimVie
ZIMV
| $38M | 0.88% |
2,725,000
| – | – |
|
27
BioMarin Pharmaceuticals
BMRN
$12.5B
| $29.6M | 0.68% |
+450,000
| New | +$30.1M |
|
28
MoonLake Immunotherapeutics
MLTX
$1.04B
| $23.9M | 0.55% |
441,000
| – | – |
|
29
Ionis Pharmaceuticals
IONS
$7.83B
| $21.9M | 0.51% |
+625,000
| New | +$23.4M |
|
30
Herbalife
HLF
$1.25B
| $20.1M | 0.46% |
3,000,000
| – | – |
|
31
Inogen
INGN
$139M
| $18.3M | 0.42% |
2,000,000
| – | – |
|
|
BKDT
32
DELISTED
Brookdale Senior Living Inc. 7.00% Tangible Equity Units
BKDT
| $17.2M | 0.4% |
250,000
| – | – |
|
33
AnaptysBio
ANAB
$1.6B
| $16.6M | 0.38% |
+1,250,000
| New | +$30.3M |
|
34
OraSure Technologies
OSUR
$241M
| $15.3M | 0.35% |
4,250,000
| – | – |
|
35
10x Genomics
TXG
$9.98B
| $14.4M | 0.33% |
+1,000,000
| New | +$15.8M |
|
|
MRUS
36
DELISTED
Merus
MRUS
| $10.5M | 0.24% |
+250,000
| New | +$12M |
|
37
Theravance Biopharma
TBPH
$884M
| $9.41M | 0.22% |
1,000,000
| – | – |
|
38
Structure Therapeutics
GPCR
$2.75B
| $8.14M | 0.19% |
+300,000
| New | +$10.6M |
|
39
Genmab
GMAB
$21.1B
| $1.04M | 0.02% |
50,000
| – | – |
|
|
BCYC
40
Bicycle Therapeutics
BCYC
$257M
| – | – |
-915,000
| Closed | -$20.7M |
|
|
SEM
41
DELISTED
Select Medical
SEM
| – | – |
-3,944,000
| Closed | -$74.1M |
|
42
SkinHealth Systems
SKIN
$89.1M
| – | – |
-1,500,000
| Closed | -$2.16M |
|
|
43
Universal Health Services
UHS
$10.3B
| – | – |
-125,000
| Closed | -$28.6M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Camber Capital Management held 43 positions worth $4.32B, up 37% from $3.15B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Camber Capital Management deployed $268M of net new capital in Q4 2024, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Pfizer: 5,000,000 shares worth $133M.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Zimmer Biomet, an estimated $96M trimmed.
- Camber Capital Management's largest Q4 2024 buy was Pfizer: 5,000,000 shares worth $133M.
- Camber Capital Management added most to Humana in Q4 2024, an estimated $121M increase.
- Camber Capital Management's biggest Q4 2024 reduction was Zimmer Biomet, cutting an estimated $96M.
- Camber Capital Management fully exited Select Medical in Q4 2024, selling an estimated $74.1M.
- Camber Capital Management's ten largest holdings make up 68% of its $4.32B portfolio in Q4 2024.
- Camber Capital Management opened 10 new positions and closed 4 in Q4 2024.
- Camber Capital Management's portfolio value rose 37% quarter-over-quarter to $4.32B.
Based on Camber Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.